Analyst Price Target Update on Qiagen N.V. (NASDAQ:QGEN)

Qiagen N.V. (NASDAQ:QGEN) shares are expected to touch $24.25 in the short term. This short term price target has been shared by 8 analysts. However, the standard deviation of short term price estimate has been valued at 1.83. The target price could hit $27 on the higher end and $22 on the lower end.

Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Citigroup maintains its rating on Qiagen N.V. (NASDAQ:QGEN). The rating major has initiated the coverage with neutral rating on the shares. The Analysts at Citigroup lowers the price target from $28 per share to $25 per share. The rating by the firm was issued on March 15, 2016. Company shares have received an average consensus rating of Hold for the current week

Qiagen N.V. (NASDAQ:QGEN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.28 points or 1.29% at $21.43 with 1,519,303 shares getting traded. Post opening the session at $21.51, the shares hit an intraday low of $21.41 and an intraday high of $21.7 and the price was in this range throughout the day. The company has a market cap of $5,002 million and the number of outstanding shares have been calculated to be 233,389,000 shares. The 52-week high of Qiagen N.V. (NASDAQ:QGEN) is $28.53 and the 52-week low is $20.1.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *